TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bleeding times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: VO₂(peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PCS score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increased airway patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lag time to LDL oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxidation rate of LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pain at the insertion site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 26-week mortality
Endpoint domain: Mortality/survival
Primary endpoint: clinical mucosal alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cytological differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: micronucleus study results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of ischemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clinical duration of neuromuscular block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC50 concentration for neuromuscular block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Box and Block Test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jebsen‐Taylor Hand Function Test (JTHF) time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum hand aperture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma γ‐tocopherol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxidized LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urolithin‐A excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent change in excess retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: mean plasma cortisol response to cosyntropin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean area under the plasma cortisol concentration-time curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: peak plasma cortisol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time for SpO2 to decrease to 98% (T98)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for SpO2 to decrease to 95% (T95)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for SpO2 to decrease to 90% (T90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of dysentery
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of respiratory infection
Endpoint domain: Adverse events/effects
Primary endpoint: Primary access circuit patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Primary target lesion patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in repeat PBxs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to detect Gleason sum ≥ 7 PCa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative predictive value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: hospital expenses
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Decrease in TP (Tissue Perfusion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in TBI (Tissue Blood Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric mean antibody titer ratios for HPV-16 and HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional Independence Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Mobility Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development quotient scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: bone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCN staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-17 cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Restoration of gastrointestinal functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normal percentage rate of lymphocytes to neutrophile granulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: recurrent serious vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality rate from worsening heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Peak rapid filling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean rate of rapid filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Opened infarct-related artery on arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TIMI frame count after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major adverse cardiovascular events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Left-ventricular end-diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NTproBNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rectal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Vitamin E level in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Susceptibility of LDL to oxidative modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine citrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean marginal bone level (MBL) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diastolic filling profile improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cIB values improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in gingival inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in tooth color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fecal fat excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRTEE total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS at daily activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in peak workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts to reach proficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach proficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: patients' understanding of CBT principles
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ADHD symptom reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conners Adult ADHD Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma anti-Xa factor activity above 0.5 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Likelihood of thrombosis in sheath catheter during PCI
Endpoint domain: Adverse events/effects
Primary endpoint: ventricular function outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tolerability and safety of naproxen solution
Endpoint domain: Adverse events/effects
Primary endpoint: Number of stressful events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FT4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FT3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Immunization activity at 19 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Myocardial infarction, stroke, or death from cardiovascular causes
Endpoint domain: Mortality/survival
Primary endpoint: Life-threatening bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Peak heart rate during 6-min walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aggregate retinal sensitivity loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IBS severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 of fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ischemic end point
Endpoint domain: Mortality/survival
Primary endpoint: Major bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement on the visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient‐Rated Tennis Elbow Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean MI ablation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean procedural time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for coronary sinus ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EPDS score ≥ 12 at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tilt test duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds ratio for premature abortion of head-up tilt testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection arrest rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage change in hexagonal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in cardiovascular risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: self-reported satisfaction with life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-reported stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: functional walking capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection rate of lung cancers
Endpoint domain: Mortality/survival
Primary endpoint: Early recall rate
Endpoint domain: Adverse events/effects
Primary endpoint: Biopsy rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak VO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak stress t‐IVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant non-CABG-related bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Median number of TF-positive microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical success after 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary angiographic patency rates at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean adjusted difference in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost per STI detected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: fever clearance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disappearance time of cervical lymph node swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in OKS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-patient stay duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total time of SI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores in the first 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FGF-23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sKlotho levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qmax improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPSS and QoL outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: treatment adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compressive strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean sweating area decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-evaluation improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of local side effects
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative cardiac surgical bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average sessions required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VISA-A score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hour glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: basal FFA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Success rate of common bile duct cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean number of attempts required for cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean time taken to achieve cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: post-prandial plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post-prandial plasma insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Two-year all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Two-year rate of stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life (Kansas City Cardiomyopathy Questionnaire summary score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: C(max) and AUC of MPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interstitial concentrations of glycerol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Interstitial concentrations of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma glycerol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean seizure durations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mean total seizure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Adherence to pharmacotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 28-day survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 90-day survival rate
Endpoint domain: Mortality/survival
Primary endpoint: rates of recovery from DIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from progression (FFP)
Endpoint domain: Mortality/survival
Primary endpoint: IA temperature decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain scores
Endpoint domain: Adverse events/effects
Primary endpoint: Cost effectiveness of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pepsinogen II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum creatinine kinase-MB and myoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: abdominal circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load <50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in urine protein/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean percentage change in bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: LC operation time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: obstacle crossing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status